|
|
| Line 269: |
Line 269: |
| |- | | |- |
| !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> MAPK signaling
| |
| |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation
| |
| |<span class="blue-text">EXAMPLE:</span> Unregulated cell division
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling
| |
| |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program
| |
| |- | | |- |
| | | | | |
| | | | |WNT signaling |
| | | | |Increased cell-proliferation, survival and chemotaxis |
| |} | | |} |
|
| |
|
